Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
In a study of patients with advanced melanoma treated with single-agent nivolumab or pembrolizumab, 25.8% achieved a complete response (CR). Approximately four out of five patients with advanced…
Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet…
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome…
Hosted by the American Thoracic Society International Health Committee, respiratory health professionals from the US, South Africa, Kenya, and Nigeria discuss their experiences with COVID-19. Challenges in Africa…
A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab…
Trainees Luke J. Rogers, Akshay Patel, and Ruth Benson discuss the CovidSurg database, which includes any patient having an operation who tested positive for COVID-19 prior to or…
A research collaboration between Georgia Tech and Emory University, with funding from the National Institutes of Health and the National Science Foundation, studied the effects of hydroxychloroquine (HCQ)…
A treatment is undergoing development in hopes to receive FDA clearance to be the first drug targeted at the third- and fourth-line space in patients with refractory renal cell carcinoma…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
